Aera Therapeutics
Aera Therapeutics is a biotechnology company focused on unlocking the potential of genetic medicines through innovative delivery platforms. Founded with a vision to overcome current delivery limitations, Aera develops proprietary lipid nanoparticles (LNPs) and protein nanoparticles (PNPs) to enable next-generation genetic medicines across various therapeutic modalities and disease areas. The company aims to expand the reach of genetic medicines to different tissues and applications, benefiting more patients worldwide.
Industries
Nr. of Employees
medium (51-250)
Aera Therapeutics
Patents
Products
Protein nanoparticle delivery platform
A delivery platform based on endogenous human proteins that self-assemble into capsid-like particles to package and deliver nucleic acid cargos with engineered modularity and targetability.
Lipid nanoparticle delivery platform
Lipid nanoparticle formulations engineered to target additional cell types and tissues beyond liver and to support broader therapeutic applications.
Therapeutic gene editing enzyme platform
A platform of compact, programmable gene editing enzymes intended to reduce packaging constraints and facilitate delivery with nanoparticle systems.
Protein nanoparticle delivery platform
A delivery platform based on endogenous human proteins that self-assemble into capsid-like particles to package and deliver nucleic acid cargos with engineered modularity and targetability.
Lipid nanoparticle delivery platform
Lipid nanoparticle formulations engineered to target additional cell types and tissues beyond liver and to support broader therapeutic applications.
Therapeutic gene editing enzyme platform
A platform of compact, programmable gene editing enzymes intended to reduce packaging constraints and facilitate delivery with nanoparticle systems.
Services
Partnership-based research to develop and optimize delivery systems (protein- and lipid-based) and associated payloads for therapeutic applications.
Services to support candidate progression including bioanalytics, DMPK, and early development planning to enable clinical entry.
Partnership-based research to develop and optimize delivery systems (protein- and lipid-based) and associated payloads for therapeutic applications.
Services to support candidate progression including bioanalytics, DMPK, and early development planning to enable clinical entry.
Expertise Areas
- Genetic medicine delivery platforms
- Protein design and engineering
- Lipid nanoparticle formulation and targeting
- Payload engineering for siRNA/ASO/mRNA/DNA/gene editors
Key Technologies
- Protein nanoparticles (PNPs)
- Lipid nanoparticles (LNPs)
- siRNA therapeutics
- Antisense oligonucleotides (ASOs)